Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy

Ann Oncol. 2012 Aug;23(8):2065-2071. doi: 10.1093/annonc/mds106. Epub 2012 May 15.

Abstract

Background: This study was conducted to determine the incidence and clinical characteristics of lacrimal drainage obstruction (LDO) in patients receiving S-1 chemotherapy.

Patients and methods: Consecutive 170 patients with gastric cancer who underwent curative surgery and received adjuvant S-1 chemotherapy were enrolled. S-1 was administered orally (40 mg/m2 b.i.d. on days 1-28 every 6 weeks) for 1 year. Ophthalmologic examinations were carried out on patients complaining of epiphora.

Results: Thirty-one patients (18%) developed epiphora. Among 31 patients, 25 underwent ophthalmologic examinations and 22 (88%) were diagnosed with LDO. The median time to the onset of LDO was 2.9 months. The most common site of obstruction was the nasolacrimal duct [86% (19/22)]; punctal [23% (5/22)] and canalicular obstruction [14% (3/22)] were also noted. In multivariate analysis, total gastrectomy [versus partial gastrectomy: hazard ratio (HR), 2.9; P=0.014] and creatinine clearance<50 ml/min (versus ≥50 ml/min: HR, 2.9; P=0.038) were independent risk factors for the development of LDO.

Conclusion: Considering the high incidence of LDO in patients receiving S-1 chemotherapy, oncologists should be alert to epiphora and cooperate with ophthalmologists in the early stages to improve the quality of life of patients and avoid more complicated ophthalmologic procedures.

MeSH terms

  • Adult
  • Aged
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Drug Combinations
  • Female
  • Humans
  • Lacrimal Duct Obstruction / chemically induced*
  • Lacrimal Duct Obstruction / pathology
  • Male
  • Middle Aged
  • Nasolacrimal Duct / drug effects
  • Nasolacrimal Duct / pathology
  • Oxonic Acid / administration & dosage
  • Oxonic Acid / adverse effects*
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / surgery
  • Tegafur / administration & dosage
  • Tegafur / adverse effects*

Substances

  • Antimetabolites, Antineoplastic
  • Drug Combinations
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid